| Donna Bilu Martin, MD | |
|
2999 Ne 191st Street, Ph1, Aventura, FL 33180 | |
| (305) 933-1151 | |
| (305) 933-8055 |
| Full Name | Donna Bilu Martin |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 20 Years |
| Location | 2999 Ne 191st Street, Aventura, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164565321 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | ME100331 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Premier Dermatology, Md, Llc | 5092094755 | 2 |
News Archive
Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.
Physicians - attendees of the 25th Annual EANM (European Association of Nuclear Medicine) Congress (October 27-31, Milan) - expressed their continuing interest in and recognition for Tektrotyd, a radiopharmaceutical responsible for significant progress in diagnostics/therapy of neuroendocrine tumours.
For patients with juvenile idiopathic arthritis in remission, withdrawal of treatment with the drug methotrexate over 12 months vs. 6 months did not reduce the rate of relapse, according to a study in the April 7 issue of JAMA.
Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.
Women giving birth after undergoing fertility treatment face an increased risk of depression compared to women ending up not having a child following fertility treatment, according to new research from the University of Copenhagen. According to the researchers, this has key implications for fertility treatment in future.
› Verified 9 days ago
| Entity Name | Premier Dermatology, Md, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285039248 PECOS PAC ID: 5092094755 Enrollment ID: O20161121000903 |
News Archive
Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.
Physicians - attendees of the 25th Annual EANM (European Association of Nuclear Medicine) Congress (October 27-31, Milan) - expressed their continuing interest in and recognition for Tektrotyd, a radiopharmaceutical responsible for significant progress in diagnostics/therapy of neuroendocrine tumours.
For patients with juvenile idiopathic arthritis in remission, withdrawal of treatment with the drug methotrexate over 12 months vs. 6 months did not reduce the rate of relapse, according to a study in the April 7 issue of JAMA.
Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.
Women giving birth after undergoing fertility treatment face an increased risk of depression compared to women ending up not having a child following fertility treatment, according to new research from the University of Copenhagen. According to the researchers, this has key implications for fertility treatment in future.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donna Bilu Martin, MD 2999 Ne 191st Street, Ph1, Aventura, FL 33180 Ph: (305) 933-1151 | Donna Bilu Martin, MD 2999 Ne 191st Street, Ph1, Aventura, FL 33180 Ph: (305) 933-1151 |
News Archive
Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent.
Physicians - attendees of the 25th Annual EANM (European Association of Nuclear Medicine) Congress (October 27-31, Milan) - expressed their continuing interest in and recognition for Tektrotyd, a radiopharmaceutical responsible for significant progress in diagnostics/therapy of neuroendocrine tumours.
For patients with juvenile idiopathic arthritis in remission, withdrawal of treatment with the drug methotrexate over 12 months vs. 6 months did not reduce the rate of relapse, according to a study in the April 7 issue of JAMA.
Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.
Women giving birth after undergoing fertility treatment face an increased risk of depression compared to women ending up not having a child following fertility treatment, according to new research from the University of Copenhagen. According to the researchers, this has key implications for fertility treatment in future.
› Verified 9 days ago
Dr. Janet Carol Teltscher, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 21150 Biscayne Blvd, Ste 102, Aventura, FL 33180 Phone: 305-933-3395 Fax: 305-935-6248 | |
Loretta M Ciraldo, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 18851 Ne 29th Ave, Suite 768, Aventura, FL 33180 Phone: 305-749-3135 Fax: 305-749-3136 | |
Mark Steven Nestor, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2925 Aventura Blvd, Ste 205, Aventura, FL 33180 Phone: 305-933-6716 Fax: 305-933-6720 | |
Carlos Cohen, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2999 Ne 191st St Ste 260, Aventura, FL 33180 Phone: 954-436-2200 Fax: 954-436-2262 | |
Newsha Lajevardi, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2801 Ne 213th St Ste 1005, Aventura, FL 33180 Phone: 305-330-9933 Fax: 305-250-2610 | |
Dr. Brian Berman, M.D., PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2925 Aventura Boulevard, S. 205, Aventura, FL 33180 Phone: 305-933-6716 Fax: 305-933-6720 |